{"gene":"CSNK1A1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2015,"finding":"Lenalidomide induces ubiquitination and degradation of CK1α by the CRL4(CRBN) E3 ubiquitin ligase (CUL4-RBX1-DDB1-CRBN); haploinsufficiency of CK1α in del(5q) MDS sensitizes cells to this degradation, providing the mechanistic basis for lenalidomide's therapeutic window in del(5q) MDS.","method":"Ubiquitination assays, immunoprecipitation, mouse-human CRBN single amino acid swap rescue experiment, mass spectrometry","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods (ubiquitination assay, IP, genetic rescue), replicated across studies, mechanistic conclusion validated in cellulo and in vivo","pmids":["26131937"],"is_preprint":false},{"year":2016,"finding":"Crystal structure (2.45 Å) of DDB1-CRBN bound to lenalidomide and CK1α shows that CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop in the kinase N-lobe; CK1α binding to CRL4(CRBN) is strictly IMiD-dependent.","method":"X-ray crystallography, binding assays, mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with functional validation, published in Nature, independently consistent with biochemical data from companion studies","pmids":["26909574"],"is_preprint":false},{"year":2011,"finding":"CKIα is a component of the β-catenin destruction complex; conditional ablation of Csnk1a1 in mouse gut triggers massive Wnt/β-catenin activation and concurrent p53 activation; combined loss of CKIα and p53 (or p21) drives invasive carcinoma, establishing CKIα as a tumour suppressor downstream of p53.","method":"Conditional knockout (Cre-lox) mouse model, histology, gene expression profiling, epistasis analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with multiple compound knockouts and defined phenotypic readouts, published in Nature","pmids":["21331045"],"is_preprint":false},{"year":2010,"finding":"CK1α phosphorylates YAP at Ser381 (after Lats primes it), creating a phosphodegron that recruits SCF(β-TRCP) E3 ubiquitin ligase leading to YAP ubiquitination and degradation; CK1δ/ε are identified as the relevant isoforms for this step.","method":"In vitro kinase assay, phospho-specific antibodies, co-immunoprecipitation, ubiquitination assay, mutagenesis","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted phosphorylation cascade in vitro plus mutagenesis of phosphodegron, multiple orthogonal methods","pmids":["20048001"],"is_preprint":false},{"year":2010,"finding":"CK1α acts as a clock regulatory kinase that phosphorylates PER1 to stimulate its degradation; siRNA knockdown of CKIα lengthens circadian period; combinatorial knockdown of CKIδ, CKIα and ERK2 dramatically lengthens period, revealing a multi-kinase network for clock robustness.","method":"Affinity chromatography/mass spectrometry target identification, siRNA knockdown, circadian reporter assays, chemical inhibition","journal":"PLoS Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — target ID by affinity-MS plus functional siRNA validation, single lab, two orthogonal approaches","pmids":["21179498"],"is_preprint":false},{"year":2011,"finding":"CK1α phosphorylates the carboxyl-terminal tail of mammalian Smoothened (mSmo) at multiple sites to induce its active conformation and promote ciliary accumulation; Hh signaling recruits CK1α to initiate mSmo phosphorylation, and phosphorylation further increases CK1α/GRK2 binding, forming a positive feedback loop.","method":"In vitro kinase assay, phosphorylation-site mutagenesis, co-immunoprecipitation, immunofluorescence, cell-based Hh signaling assays","journal":"PLoS Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution plus mutagenesis plus cell-based functional readout, single lab but multiple orthogonal methods","pmids":["21695114"],"is_preprint":false},{"year":2005,"finding":"CKIα phosphorylates FADD at Ser194 both in vitro and in vivo; FADD-CKIα association regulates subcellular localization of FADD, with phosphorylated FADD co-localizing with CKIα at spindle poles in metaphase; CKIα inhibition prevents Taxol-induced mitotic arrest and blocks mitogen-induced proliferation.","method":"In vitro kinase assay, co-immunoprecipitation, immunofluorescence, pharmacological inhibition, splenocyte proliferation assay","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation assay with defined substrate site, co-IP, localization, and functional rescue with phospho-site mutant mice","pmids":["16061179"],"is_preprint":false},{"year":2015,"finding":"CK1α phosphorylates FADD downstream of oncogenic KRAS, promoting mitotic entry; deletion of CK1α in KRAS-mutant mice abrogates FADD phosphorylation and suppresses lung cancer development; phosphorylated FADD interacts with PLK1, AURKA, and BUB1 in a CK1α-dependent manner during G2/M.","method":"Conditional knockout mouse model, mass spectrometry, immunohistochemistry, in vivo imaging, kinase inhibitor treatment","journal":"Science Signaling","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic evidence plus MS substrate identification plus functional phenotype, single lab","pmids":["25628462"],"is_preprint":false},{"year":2009,"finding":"CK1α forms a stable complex with MDM2 in undamaged cells; depletion or inhibition of CK1α stabilizes p53 and destabilizes E2F-1, indicating CK1α is a negative regulator of p53 and positive regulator of E2F-1 through the MDM2-CK1α complex.","method":"siRNA knockdown, pharmacological inhibition (D4476), co-immunoprecipitation of endogenous proteins, western blot","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP of endogenous proteins plus RNAi and chemical inhibition with consistent results, single lab","pmids":["19759023"],"is_preprint":false},{"year":2014,"finding":"Csnk1a1 knockdown in AML cells results in decreased Rps6 phosphorylation and increased p53 activity leading to myeloid differentiation; p53-null leukemias are insensitive to Csnk1a1 knockdown, placing CK1α upstream of p53 in a leukemia-survival pathway.","method":"shRNA knockdown, in vivo pooled shRNA screen, gene expression profiling, pharmacological inhibition (D4476), flow cytometry","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic screen plus epistasis analysis (p53-null rescue), functional cellular and molecular readouts","pmids":["24616378"],"is_preprint":false},{"year":2008,"finding":"CKIα is associated with the nuclear poly(A) polymerase Star-PAP and directly phosphorylates it; CKIα and PIPKIα are both required for expression of a subset of Star-PAP target mRNAs; CKIα activity is PI-4,5-P2-sensitive within the Star-PAP complex.","method":"Mass spectrometry, co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, qRT-PCR","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation assay plus co-IP plus functional knockdown, single lab","pmids":["18305108"],"is_preprint":false},{"year":1999,"finding":"CK1 phosphorylates p53 at Thr18 in vitro; this phosphorylation requires prior phosphorylation of Ser15, establishing a phosphorylation-priming hierarchy at the MDM2-binding domain of p53.","method":"In vitro kinase assay with recombinant CK1δ and p53, phospho-site mapping","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution but single lab, single method, no mutagenesis confirmation of functional consequence","pmids":["10606744"],"is_preprint":false},{"year":2009,"finding":"CK1α and CK1δ directly phosphorylate p53 preferentially at S20 (not S6); affinity for full-length p53 is ~1000-fold higher than for the N-terminal peptide, implicating a remote docking site mapped to the K221RQK224 loop; CK1γ1 does not phosphorylate p53.","method":"In vitro kinase assay with recombinant isoforms, Km determination, mutagenesis of docking loop","journal":"Cellular and Molecular Life Sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple isoforms plus mutagenesis, single lab","pmids":["20041275"],"is_preprint":false},{"year":2008,"finding":"PML enhances CK1-mediated phosphorylation of p53 at Thr18 in response to DNA damage; CK1 interacts with endogenous p53 and PML and this interaction is enhanced by genotoxic stress; PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, protecting p53 from MDM2-mediated degradation.","method":"Co-immunoprecipitation, immunofluorescence, phospho-specific antibodies, CK1 inhibitor treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of endogenous proteins plus localization plus functional inhibitor readout, single lab, multiple complementary methods","pmids":["18246126"],"is_preprint":false},{"year":2004,"finding":"CK1 phosphorylates NFAT1 specifically at the SRR-1 motif (required for nuclear import); CK1 exists with NFAT1 in a high-molecular-weight complex in resting T cells but dissociates upon activation; a conserved docking motif in NFAT proteins is required for CK1 interaction, and its mutation causes constitutive nuclear localization of NFAT1.","method":"In vitro kinase assay, co-immunoprecipitation, mutagenesis, nuclear localization imaging","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation plus docking-motif mutagenesis with functional nuclear-localization readout, multiple orthogonal methods","pmids":["15121840"],"is_preprint":false},{"year":2018,"finding":"CK1 is the executioner kinase for p63 activation in oocyte DNA-damage quality control; both CHK2 (priming) and CK1 (execution) phosphorylations are required to induce p63's active tetrameric conformation; CK1 inhibition rescues primary oocytes from chemotherapy-induced apoptosis.","method":"Biochemical phosphorylation assays, structural analysis of p63 conformational changes, mouse primordial follicle experiments, CK1 inhibitor rescue","journal":"Nature Structural & Molecular Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assays, structural data on p63 conformational change, and in vivo rescue experiment, multiple orthogonal methods","pmids":["29483652"],"is_preprint":false},{"year":2020,"finding":"CK1α, CK1δ, and CK1ε are necrosome components that directly phosphorylate RIPK3 at Ser227 to activate necroptosis; this interaction depends on RIPK3 kinase activity; a RIPK3 CK1-recognition-motif mutant fails to be phosphorylated at S227, does not bind MLKL, and cannot activate necroptosis.","method":"Tandem immunoprecipitation, in vitro kinase assay, CK1 loss-of-function, RIPK3 recognition-motif mutagenesis, necroptosis assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro phosphorylation assay plus genetic loss-of-function plus rescue mutagenesis with functional cell death readout, multiple orthogonal methods","pmids":["31932442"],"is_preprint":false},{"year":2017,"finding":"CSNK1a1 directly binds and phosphorylates PRMT1 to control its genomic targeting; loss of CSNK1a1 in epidermal progenitors (mouse and human) abolishes progenitor self-renewal and leads to premature differentiation through derepression of GRHL3.","method":"Mass spectrometry (PRMT1 interactome), co-immunoprecipitation, in vitro kinase assay, conditional mouse knockout, human mosaic epidermis in vivo regeneration","journal":"Developmental Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — MS-identified interaction confirmed by co-IP and in vitro phosphorylation, plus in vivo genetic validation in mouse and human tissue","pmids":["28943242"],"is_preprint":false},{"year":2018,"finding":"CK1α suppresses NSCLC tumour growth by binding the C-terminal tail of PTEN and enhancing PTEN stability and activity by competitively antagonizing NEDD4-1-induced polyubiquitination and abrogating PTEN phosphorylation, thereby inhibiting AKT and activating FOXO3a-induced Atg7 transcription and autophagy.","method":"Co-immunoprecipitation, ubiquitination assay, in vitro binding assay, CK1α knockdown/overexpression, xenograft models","journal":"Nature Cell Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus ubiquitination assay plus xenograft functional validation, multiple orthogonal methods replicated in vivo","pmids":["29593330"],"is_preprint":false},{"year":2020,"finding":"CK1α phosphorylates CBX4 at T437, which facilitates CBX4 ubiquitination at K178 and K280 and subsequent CHIP-mediated degradation; TNFα reduces CK1α-mediated CBX4 phosphorylation; CK1α suppresses osteosarcoma cell migration and invasion through CBX4 inhibition.","method":"In vitro kinase assay, co-immunoprecipitation, ubiquitination assay, phospho-site mutagenesis, cell migration/invasion assays","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with phospho-site mutagenesis plus ubiquitination assay plus functional cell biology readout, multiple orthogonal methods","pmids":["32111827"],"is_preprint":false},{"year":2013,"finding":"CK1α phosphorylates RAPGEF2 in response to pro-motility factors, together with IKKβ, leading to proteasomal degradation via SCF(βTrCP); failure to degrade RAPGEF2 sustains Rap1 activity and inhibits HGF-induced cell migration.","method":"Phosphorylation assays, co-immunoprecipitation, degradation-resistant mutant expression, cell migration assays, xenograft metastasis model","journal":"Developmental Cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation assay plus co-IP plus functional mutant rescue plus in vivo metastasis, single lab","pmids":["24290981"],"is_preprint":false},{"year":2011,"finding":"In the canonical Wnt pathway, CK1α associates with the LRP5/6/p120-catenin complex after Wnt3a stimulation in a CK1ε-dependent manner and within a complex with axin; CK1α participates in the release of p120-catenin from the LRP5/6 complex to activate downstream signalling.","method":"Co-immunoprecipitation, siRNA knockdown, Wnt reporter assays, sequential epistasis analysis","journal":"Molecular and Cellular Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus siRNA epistasis with reporter assay readout, single lab, multiple complementary approaches","pmids":["21606194"],"is_preprint":false},{"year":2005,"finding":"CK1 phosphorylates Ci (Drosophila Gli) at three PKA/GSK3-primed serine clusters, creating Slimb/β-TRCP binding sites that cooperatively recruit SCF(Slimb) ubiquitin ligase for Ci proteolytic processing; CKIα and DBT/CKIε act in conjunction for this step.","method":"In vitro kinase assay, mutagenesis of phosphorylation clusters, Slimb binding assay, Drosophila in vivo epistasis","journal":"Developmental Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution plus mutagenesis plus in vivo Drosophila genetic validation, multiple orthogonal methods","pmids":["16326393"],"is_preprint":false},{"year":2014,"finding":"CK1 phosphorylates Ci/Gli activator isoforms at multiple Ser/Thr-rich degrons downstream of Costal2 and Sufu to inhibit HIB (Cullin3 E3 ligase substrate receptor)-mediated Ci(A) degradation, sustaining Hh pathway activity; Gli(A) is similarly regulated in vertebrates.","method":"In vitro kinase assay, mutagenesis, co-immunoprecipitation, Drosophila genetics, mammalian cell Hh reporter assays","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation plus mutagenesis plus in vivo Drosophila and mammalian cell evidence, multiple orthogonal methods","pmids":["25512501"],"is_preprint":false},{"year":2006,"finding":"CK1 phosphorylates β-catenin at Ser45; the first armadillo repeat of β-catenin is required for high-affinity CK1 recognition (removing it raises Km ~50-fold); α-catenin binding to β-catenin's N-terminal region prevents CK1-mediated Ser45 phosphorylation.","method":"In vitro kinase assay with deletion mutants, Km determination, competition assay","journal":"PNAS","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with systematic mutants defining docking determinants, single lab, multiple substrate variants tested","pmids":["17172446"],"is_preprint":false},{"year":2007,"finding":"CK1 initiates phosphorylation of APC repeat-3 (R3) at S1510 and S1505 via non-canonical determinants; phospho-S1505 primes GSK3 phosphorylation of S1501; phospho-S1501 in turn triggers hierarchical CK1 phosphorylation of S1504 and S1507, completing a six-step cascade required for β-catenin degradation.","method":"In vitro kinase assay with variably phosphorylated peptides, Edman degradation phospho-site mapping","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — detailed in vitro reconstitution of the phosphorylation cascade, single lab, systematic peptide analysis","pmids":["17910481"],"is_preprint":false},{"year":2005,"finding":"CK1 directly phosphorylates LEF-1 and disrupts the LEF-1/β-catenin complex (without impairing LEF-1/DNA binding); this requires co-phosphorylation of β-catenin; CK1-dependent phosphorylation inhibits LEF-1/β-catenin transcriptional activity, establishing CK1 as a second-level negative regulator of canonical Wnt signalling.","method":"In vitro kinase assay, GST pulldown, electrophoretic mobility shift assay, luciferase reporter assay","journal":"Cellular and Molecular Life Sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation assay plus protein interaction disruption assay plus reporter readout, single lab","pmids":["15747065"],"is_preprint":false},{"year":2005,"finding":"CK1α phosphorylates hnRNP-C at Ser240 and Ser225-228 in response to physiological H2O2; phosphorylation at CK1α sites causes 14–500-fold decrease in hnRNP-C RNA-binding affinity, as shown by phosphomimetic mutations.","method":"Kinase purification and identification by tandem MS, in vitro kinase assay, co-immunoprecipitation, fluorescence RNA binding assay with phosphomimetic mutants","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — kinase identified by MS purification, in vitro phosphorylation confirmed, functional consequence demonstrated by RNA binding assay with phosphomimetics","pmids":["15687492"],"is_preprint":false},{"year":2019,"finding":"FAM83D recruits CK1α to the mitotic spindle; cells lacking FAM83D or carrying CK1α-binding-deficient FAM83DF283A/F283A knockin mutations display spindle positioning defects and prolonged mitosis; artificial re-delivery of CK1α to the spindle rescues these defects.","method":"CRISPR/Cas9 knockin, live-cell imaging, immunofluorescence, FAM83D knockout, spindle positioning assay","journal":"EMBO Reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockin plus knockout with functional rescue, two orthogonal localization approaches, specific mechanistic pathway placement","pmids":["31338967"],"is_preprint":false},{"year":2020,"finding":"Truncating RNF43 cancer mutations trap CK1 at the plasma membrane by disrupting a ubiquitin-independent suppressor function of the RNF43 cytosolic tail, thereby preventing β-catenin turnover and driving ligand-independent Wnt target gene transcription.","method":"Gene editing of human colon stem cells, co-immunoprecipitation, luciferase reporter assay, proximity ligation assay","journal":"EMBO Journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR gene editing plus co-IP plus reporter assay, single lab, multiple approaches","pmids":["32965059"],"is_preprint":false},{"year":2009,"finding":"CK1α autophosphorylates its own C-terminal residues (last four Ser/Thr); this autophosphorylation inhibits catalytic activity; lambda phosphatase treatment activates CK1α by 80–100%, and re-autophosphorylation re-inhibits it, establishing autophosphorylation as a regulatory mechanism.","method":"Mass spectrometry of autophosphorylation sites, site-directed mutagenesis to Ala, lambda phosphatase treatment, in vitro kinase assay","journal":"Journal of Cellular Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS site identification plus mutagenesis plus phosphatase activation/re-inhibition cycle, multiple orthogonal methods, single lab","pmids":["19115251"],"is_preprint":false},{"year":2007,"finding":"CK1 (alpha, delta, epsilon isoforms) binds axin and can be purified by affinity chromatography on an immobilised axin fragment (residues 495–684); the purified enzymes retain high kinase activity, confirming a direct physical CK1α-axin interaction.","method":"Affinity chromatography, kinase activity assay","journal":"Protein Expression and Purification","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct binding demonstrated by affinity chromatography, replicated with two different matrix formats, limited to physical interaction without full mechanistic context","pmids":["17434749"],"is_preprint":false},{"year":2017,"finding":"Oncogenic RAS elevates CK1α activity to phosphorylate FOXO4 at Ser265/268, triggering its proteasomal degradation; this is partially primed by AKT effectors of RAS signalling; dual inhibition of CK1α and the proteasome synergistically inhibits RAS-mutant cancer cell growth.","method":"In vitro kinase assay, phospho-site mutagenesis, CK1α inhibition, FOXO4 stability assays, cell viability assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with phospho-site mutagenesis plus functional cell-biology readout, single lab","pmids":["28945225"],"is_preprint":false},{"year":2020,"finding":"FAM83F is farnesylated and interacts with CK1α at the plasma membrane; this interaction is essential for FAM83F-mediated Wnt pathway activation; a farnesyl-deficient FAM83F knockin redirects the FAM83F-CK1α complex away from the plasma membrane and attenuates Wnt signalling.","method":"Co-immunoprecipitation, CRISPR knockin of farnesyl-deficient mutant, Wnt reporter assay, Xenopus axis duplication assay","journal":"Life Science Alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus CRISPR knockin with Wnt reporter and Xenopus functional assay, single lab, multiple complementary methods","pmids":["33361109"],"is_preprint":false},{"year":2017,"finding":"Decreased CK1α abundance in WNT-driven colorectal tumours (relative to normal tissue) enhances cellular sensitivity to CK1α activators; the small-molecule CK1α activator SSTC3 inhibits CRC xenograft growth; knockdown of CK1α increases sensitivity to SSTC3.","method":"Xenograft mouse models, CK1α knockdown, CK1α activator SSTC3 treatment, patient-derived xenograft","journal":"Science Signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo xenograft with genetic validation (CK1α knockdown), single lab, functional pharmacology readout","pmids":["28655862"],"is_preprint":false},{"year":2008,"finding":"CK1 phosphorylates RhoB specifically at Ser185 in vitro and in cells; phosphorylation by CK1 inhibits RhoB, and CK1 inhibition activates RhoB-dependent actin stress fiber formation and EGF receptor stabilization; RhoA and RhoC are not phosphorylated by CK1.","method":"In vitro kinase assay, mass spectrometry phospho-site mapping, site-directed mutagenesis, CK1 inhibitors, immunofluorescence","journal":"Experimental Cell Research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with MS-confirmed site plus mutagenesis plus functional cell biology, single lab","pmids":["18590726"],"is_preprint":false},{"year":2007,"finding":"CK1 phosphorylates PKD2 at Ser244 in response to CCK2R activation; this phosphorylation blocks nuclear export of active PKD2 by preventing Crm-1 interaction, and is prerequisite for efficient phosphorylation of the nuclear PKD2 substrate HDAC7.","method":"In vitro kinase assay, co-immunoprecipitation, subcellular fractionation, nuclear export inhibition, mutagenesis","journal":"EMBO Journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus functional nuclear-localization and substrate readout, single lab","pmids":["17962809"],"is_preprint":false},{"year":2002,"finding":"The 'L' insert (exon L, 28 aa in catalytic domain) of CK1αL acts as a nuclear localization signal; CK1αL concentrates in the nucleus while CK1α is predominantly cytoplasmic; the L insert increases Km for ATP ~2-fold, decreases CKI-7 sensitivity, and accelerates protein turnover (half-life 100 min vs. 400 min for CK1α).","method":"Splice variant expression in Cos-7 cells, immunofluorescence, in vitro kinase assay, protein stability assay","journal":"Journal of Cellular Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments plus biochemical characterization, single lab, multiple orthogonal readouts","pmids":["12210746"],"is_preprint":false},{"year":2022,"finding":"Autophosphorylation of a conserved threonine (T220 equivalent) in the αG helix of CK1 alters the conformation of the substrate binding cleft, decreasing activity toward most substrates while increasing it toward specific high-affinity substrates; disrupting T220 autophosphorylation rewires CK1 signalling in S. pombe (confirmed by quantitative phosphoproteomics).","method":"Crystal structure of autophosphorylated CK1, molecular dynamics simulation, in vitro kinase assay, mutagenesis, quantitative phosphoproteomics","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus MD simulations plus mutagenesis plus quantitative phosphoproteomics, multiple orthogonal methods in one rigorous study","pmids":["35353987"],"is_preprint":false},{"year":2013,"finding":"CK1 transmits the signal to stall cytokinesis in a mitotic checkpoint by phosphopriming the SPB scaffold Sid4 for Dma1-mediated ubiquitination; CK1 accumulates at spindle pole bodies during mitotic arrest and stably associates with SPB components including Sid4.","method":"Yeast genetics, co-immunoprecipitation, kinase assay, SPB localization by fluorescence microscopy","journal":"Current Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis plus SPB localization plus kinase assay in fission yeast, single lab","pmids":["24055157"],"is_preprint":false},{"year":2022,"finding":"Mutation of PER2 residues essential for CK1 interaction abolishes PER phosphorylation and CLOCK hyperphosphorylation in cells and mice, resulting in PER stabilization and arrhythmic PER abundance; mice show robust short-period locomotor rhythms despite low-amplitude molecular rhythms, demonstrating PER acts as CK1 scaffold.","method":"Site-directed mutagenesis, CRISPR knock-in mice, circadian locomotor analysis, western blot for phosphorylation","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutagenesis in cells plus knock-in mouse model with both molecular and behavioural readouts, multiple orthogonal approaches","pmids":["35810166"],"is_preprint":false},{"year":2023,"finding":"The phosphorylated FASP region of PER2 directly docks into conserved anion-binding sites near the CK1δ active site to inhibit CK1 activity (product inhibition); crystal structures with molecular dynamics simulations reveal the pFASP-CK1δ interface; limiting FASP phosphorylation reduces product inhibition, decreasing PER2 stability and shortening circadian period.","method":"Co-crystal structure of pFASP-CK1δ, molecular dynamics simulations, site-directed mutagenesis, circadian period assay in human cells","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — co-crystal structure plus MD simulations plus mutagenesis plus functional period assay, multiple orthogonal methods in one rigorous study","pmids":["37207626"],"is_preprint":false},{"year":2018,"finding":"CK1α collaborates with DBT/CK1δ in the Drosophila clock: CK1α promotes PER nuclear localization by antagonizing DBT-dependent inhibition of nuclear translocation; once in the nucleus, CK1α enhances DBT-dependent PER phosphorylation and degradation.","method":"Drosophila genetics (knockdown/overexpression), locomotor rhythm analysis, nuclear/cytoplasmic fractionation, phosphorylation assays","journal":"Journal of Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Drosophila genetic analysis with localization and phosphorylation readouts, single lab","pmids":["30373768"],"is_preprint":false},{"year":2024,"finding":"SJ3149, a selective CK1α degrader developed through structure-guided SAR around CRBN ligands, shows broad antiproliferative activity correlated with MDM2 inhibitor Nutlin-3a response across 115 cancer cell lines; co-crystal structure of SJ3149 with CK1α+CRBN+DDB1 explains improved degradation properties.","method":"Structure-guided medicinal chemistry, co-crystal structure, proteomics, PRISM screen, cell viability panel","journal":"Nature Communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — co-crystal structure plus PRISM screen correlative evidence, single study, mechanistic link to p53 inferred from correlation with Nutlin-3a","pmids":["38228616"],"is_preprint":false},{"year":2017,"finding":"CK1α ablation in keratinocytes stabilises both β-catenin and p53; epidermal hyperpigmentation following CK1α loss requires p53-dependent upregulation of KitL (Kit ligand); co-ablation of CK1α and p53 fails to induce hyperpigmentation, and KitL/Kit pathway inhibition abrogates it.","method":"Conditional knockout mice (K14-Cre-ERT2), double knockout (CK1α/p53), transcriptome analysis, antibody/inhibitor rescue experiments","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional single and double knockouts with molecular and pharmacological rescue, multiple orthogonal readouts","pmids":["28878021"],"is_preprint":false},{"year":2013,"finding":"Reduced Csnk1a1 abundance downstream of DNA damage activates Wnt/β-catenin signalling in mouse embryonic stem cells in a p53-independent manner, limiting DNA-damage-induced apoptosis; this places CK1α as an inhibitor of β-catenin whose loss links DNA damage to Wnt activation.","method":"RNAi screen, transcriptomics, phosphoproteomics, gene deletion (p53 KO), Wnt reporter assay","journal":"Science Signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systems-biology screen plus genetic validation (p53-independent Wnt activation), multiple data types, single lab","pmids":["23354688"],"is_preprint":false}],"current_model":"CK1α (CSNK1A1) is a constitutively active, autophosphorylation-regulated serine/threonine kinase that acts at multiple nodes in Wnt/β-catenin (phosphorylating β-catenin Ser45, APC, LEF-1, axin-bound complexes), Hedgehog (phosphorylating Smoothened and Ci/Gli), p53 (phosphorylating p53 Thr18/Ser20 and forming a stable MDM2-CK1α complex), YAP (creating a phosphodegron for SCF-βTrCP), FADD/RIPK3 (necroptosis), NFAT1, FOXO, PER (circadian clock), PRMT1 (epidermal progenitor maintenance), and multiple other pathways; its subcellular targeting is controlled by scaffold proteins—notably FAM83D at the mitotic spindle—while its activity is regulated by C-terminal autophosphorylation and, pathologically, by IMiD-induced CRL4(CRBN)-mediated degradation that underlies lenalidomide efficacy in del(5q) MDS."},"narrative":{"mechanistic_narrative":"CK1α (CSNK1A1) is a constitutively active serine/threonine kinase that functions as a hierarchical, priming-dependent regulator of protein stability and signalling across the Wnt/β-catenin, Hedgehog, p53, Hippo (YAP), circadian, and cell-death pathways [PMID:21331045, PMID:20048001, PMID:16326393, PMID:31932442]. A recurring theme is that CK1α phosphorylation creates phosphodegrons that license SCF(β-TrCP)/Slimb- or other E3-mediated ubiquitination and degradation of its substrates: it primes/completes β-catenin destruction-complex turnover by phosphorylating β-catenin at Ser45 and APC repeat-3 in a multi-step cascade [PMID:17172446, PMID:17910481], phosphorylates YAP Ser381 to recruit SCF(β-TRCP) [PMID:20048001], phosphorylates Ci/Gli to direct SCF(Slimb) processing [PMID:16326393], and phosphorylates PER1/PER2 for clock-protein degradation [PMID:21179498, PMID:35810166]. In vivo, CK1α acts as a tumour suppressor in the gut, where its loss triggers concurrent Wnt and p53 activation and, when combined with p53 loss, drives invasive carcinoma [PMID:21331045]; it also restrains p53 through a stable MDM2–CK1α complex and direct phosphorylation of the p53 N-terminus [PMID:19759023, PMID:10606744, PMID:20041275]. CK1α additionally executes apoptotic and necroptotic programs by activating p63 and by phosphorylating RIPK3 at Ser227 within the necrosome [PMID:29483652, PMID:31932442]. Its catalytic output is autoregulated: C-terminal autophosphorylation inhibits activity, while autophosphorylation of a conserved αG-helix threonine remodels the substrate cleft to rewire substrate selectivity [PMID:19115251, PMID:35353987]. Substrate and spatial specificity are imposed by scaffold/docking partners—axin, FAM83D at the mitotic spindle, FAM83F at the plasma membrane, and PER as a clock scaffold—that localize the kinase to defined complexes [PMID:17434749, PMID:31338967, PMID:33361109, PMID:35810166]. Pharmacologically, IMiDs such as lenalidomide convert CK1α into a neosubstrate of the CRL4(CRBN) E3 ligase via a CRBN/lenalidomide-formed interface engaging the CK1α kinase N-lobe, and CK1α haploinsufficiency in del(5q) MDS underlies the therapeutic window of this degradation [PMID:26131937, PMID:26909574].","teleology":[{"year":1999,"claim":"Established that CK1 phosphorylates the p53 N-terminal MDM2-binding domain in a priming-dependent manner, introducing CK1 as a regulator of the p53–MDM2 axis.","evidence":"In vitro kinase assay with recombinant CK1δ and p53, phospho-site mapping","pmids":["10606744"],"confidence":"Medium","gaps":["Used CK1δ, not CK1α, in a peptide context","No mutagenesis confirming the functional consequence in cells","Did not address docking determinants on full-length p53"]},{"year":2004,"claim":"Showed CK1 controls NFAT1 nuclear import through SRR-1 phosphorylation and a docking-motif-dependent association, defining CK1 as a gatekeeper of NFAT subcellular localization.","evidence":"In vitro kinase assay, co-IP, docking-motif mutagenesis, nuclear localization imaging","pmids":["15121840"],"confidence":"High","gaps":["CK1 isoform specificity not fully resolved","Mechanism of signal-induced complex dissociation upon activation not defined"]},{"year":2005,"claim":"Connected CK1α to mitotic regulation and to negative control of canonical Wnt output by phosphorylating FADD (spindle-pole localized) and LEF-1 to disrupt the LEF-1/β-catenin complex.","evidence":"In vitro kinase assays, co-IP, immunofluorescence, EMSA, luciferase reporter, splenocyte proliferation","pmids":["16061179","15747065"],"confidence":"High","gaps":["How CK1α is recruited to spindle poles not yet defined","Physiological trigger of LEF-1 phosphorylation in vivo unclear"]},{"year":2006,"claim":"Defined the docking determinants for substrate recognition on β-catenin, showing the first armadillo repeat and α-catenin binding govern CK1 access to Ser45.","evidence":"In vitro kinase assay with deletion mutants, Km determination, competition assay","pmids":["17172446"],"confidence":"Medium","gaps":["Reconstituted in vitro; in-complex regulation by axin/APC not addressed here","Single lab"]},{"year":2008,"claim":"Extended CK1α substrate scope to RNA-binding proteins and small GTPases, phosphorylating hnRNP-C, Star-PAP, and RhoB to modulate RNA binding, mRNA expression, and cytoskeletal dynamics.","evidence":"MS kinase identification, in vitro kinase assays, co-IP, RNA-binding and immunofluorescence functional readouts","pmids":["15687492","18305108","18590726"],"confidence":"Medium","gaps":["Cellular contexts for each substrate not fully linked","PI-4,5-P2 sensitivity of CK1α within Star-PAP complex not structurally explained"]},{"year":2009,"claim":"Revealed both an autoregulatory brake (C-terminal autophosphorylation inhibits activity) and a p53-suppressive function via a stable MDM2–CK1α complex with defined S20 docking on full-length p53.","evidence":"MS autophosphorylation site mapping, phosphatase activation cycle, mutagenesis, reciprocal endogenous co-IP, RNAi, chemical inhibition","pmids":["19115251","19759023","20041275"],"confidence":"Medium","gaps":["Structural basis of the MDM2–CK1α interface not resolved","How autophosphorylation status integrates with substrate selection in vivo unclear"]},{"year":2010,"claim":"Placed CK1 in the Hippo and circadian pathways by phosphorylating YAP Ser381 to create a β-TRCP phosphodegron and PER1 to drive its degradation, generalizing the phosphodegron mechanism.","evidence":"In vitro kinase cascade reconstitution, phospho-antibodies, ubiquitination assay; affinity-MS, siRNA, circadian reporter assays","pmids":["20048001","21179498"],"confidence":"Medium","gaps":["Relative contributions of CK1α vs CK1δ/ε to YAP turnover not isolated","Clock kinase network redundancy complicates CK1α-specific assignment"]},{"year":2011,"claim":"Demonstrated in vivo that CK1α is a destruction-complex component and tumour suppressor whose ablation co-activates Wnt and p53, and detailed its dual roles in Hedgehog (Smoothened activation) and Wnt receptor signalling.","evidence":"Conditional knockout mouse epistasis; in vitro kinase, mutagenesis, immunofluorescence, Hh/Wnt reporter and co-IP epistasis","pmids":["21331045","21695114","21606194"],"confidence":"High","gaps":["Context that switches CK1α between Smoothened activation and β-catenin destruction not defined","Mechanism coupling CK1α loss to p53 activation in gut left open"]},{"year":2014,"claim":"Positioned CK1α upstream of p53 in leukemia survival and refined Hedgehog control, showing CK1α knockdown induces p53-dependent myeloid differentiation and CK1 sustains Ci/Gli activator isoforms.","evidence":"In vivo pooled shRNA screen, p53-null rescue epistasis, expression profiling; in vitro kinase, mutagenesis, Drosophila and mammalian Hh assays","pmids":["24616378","25512501"],"confidence":"High","gaps":["Direct CK1α substrate linking it to Rps6/p53 axis in AML not identified","Switch between Ci/Gli degradation and stabilization not mechanistically reconciled"]},{"year":2015,"claim":"Defined the therapeutically pivotal IMiD mechanism: lenalidomide converts CK1α into a CRL4(CRBN) neosubstrate, and del(5q) CK1α haploinsufficiency underlies the MDS therapeutic window; also linked CK1α–FADD to oncogenic KRAS-driven mitosis.","evidence":"Ubiquitination assays, IP, mouse-human CRBN swap rescue, MS; conditional KO mouse, MS, in vivo imaging","pmids":["26131937","25628462"],"confidence":"High","gaps":["Why CK1α dosage sensitivity is unique to del(5q) not fully explained at the time","Endogenous (IMiD-independent) regulators of CK1α turnover unknown"]},{"year":2016,"claim":"Provided the structural basis of IMiD-dependent neosubstrate recognition, showing CRBN and lenalidomide jointly form the binding surface for a CK1α N-lobe β-hairpin loop.","evidence":"2.45 Å X-ray crystallography of DDB1-CRBN–lenalidomide–CK1α, binding assays, mutagenesis","pmids":["26909574"],"confidence":"High","gaps":["Does not address selectivity among CK1 isoforms for degradation","Native CK1α regulation independent of CRBN not addressed"]},{"year":2017,"claim":"Expanded CK1α into epithelial/progenitor biology and oncogenic RAS signalling: it phosphorylates PRMT1 to maintain epidermal progenitors, FOXO4 to drive its degradation, and its loss stabilizes both β-catenin and p53 to drive p53/KitL-dependent pigmentation.","evidence":"MS interactomes, co-IP, in vitro kinase, conditional/human mosaic knockouts; double KO mice with pharmacological rescue; CK1α activator xenografts","pmids":["28943242","28945225","28878021","28655862"],"confidence":"High","gaps":["Tissue-specific determinants of CK1α substrate choice not unified","Whether CK1α activators are broadly tractable therapeutically remains untested beyond CRC models"]},{"year":2018,"claim":"Identified CK1α as an executioner kinase for cell-fate decisions, activating p63 in oocyte DNA-damage QC, stabilizing PTEN to promote autophagy/tumour suppression, and cooperating with DBT in clock PER localization.","evidence":"Biochemical/structural p63 assays with in vivo rescue; co-IP, ubiquitination, xenografts; Drosophila genetics and fractionation","pmids":["29483652","29593330","30373768"],"confidence":"High","gaps":["How CK1α is activated specifically upon DNA damage in oocytes unclear","CK1α–PTEN versus CK1α–p53 tumour-suppressive arms not integrated"]},{"year":2019,"claim":"Established scaffold-directed spatial control of CK1α by FAM83D, which recruits the kinase to the mitotic spindle to ensure correct spindle positioning and mitotic timing.","evidence":"CRISPR knockin of CK1α-binding-deficient FAM83D, live-cell imaging, knockout, artificial re-delivery rescue","pmids":["31338967"],"confidence":"High","gaps":["Spindle-localized CK1α substrates not enumerated","Relationship to FADD-spindle phosphorylation not connected"]},{"year":2020,"claim":"Defined CK1α as a necrosome component phosphorylating RIPK3 Ser227 to license necroptosis, and identified additional substrate (CBX4) and localization controls (FAM83F farnesylation; RNF43-mediated membrane trapping in cancer).","evidence":"Tandem IP, in vitro kinase, RIPK3 recognition-motif rescue, necroptosis assays; CBX4 phospho/ubiquitination assays; CRISPR knockin and PLA","pmids":["31932442","32111827","33361109","32965059"],"confidence":"High","gaps":["Isoform redundancy (α/δ/ε) in necrosome not dissected","How membrane-trapped CK1α alters its destruction-complex function quantitatively unclear"]},{"year":2022,"claim":"Revealed a second, conformational layer of autoregulation—αG-helix threonine autophosphorylation remodels the substrate cleft to rewire substrate selectivity—and showed PER itself scaffolds CK1 to control clock phosphorylation in vivo.","evidence":"Crystal structure, MD simulations, kinase assays, phosphoproteomics; CRISPR knock-in mice with locomotor and biochemical readouts","pmids":["35353987","35810166"],"confidence":"High","gaps":["Physiological signals controlling αG autophosphorylation in mammalian cells unknown","How conformational rewiring intersects with scaffold-based targeting not addressed"]},{"year":2023,"claim":"Provided structural mechanism for substrate-driven product inhibition of CK1, with the phosphorylated PER2 FASP region docking near the active site to inhibit the kinase and tune circadian period.","evidence":"Co-crystal structure of pFASP–CK1δ, MD simulations, mutagenesis, circadian period assays in human cells","pmids":["37207626"],"confidence":"High","gaps":["Studied with CK1δ; generality to CK1α not directly shown","Whether other substrates exert analogous product inhibition unknown"]},{"year":2024,"claim":"Advanced CK1α as a tractable degradation target with a selective CRBN-based degrader (SJ3149) whose antiproliferative activity tracks with p53 (Nutlin-3a) sensitivity, reinforcing the CK1α–p53 therapeutic axis.","evidence":"Structure-guided medicinal chemistry, co-crystal with CK1α+CRBN+DDB1, proteomics, PRISM screen, viability panel","pmids":["38228616"],"confidence":"Medium","gaps":["p53 link inferred from correlation rather than direct mechanism","On-target versus off-target degradation contributions to phenotype not fully separated"]},{"year":null,"claim":"How CK1α's constitutive activity is selectively channeled to opposing outcomes (e.g., β-catenin destruction vs Smoothened activation; p53 suppression vs activation) through the combined logic of scaffold-based localization, docking-site recognition, and autophosphorylation-driven conformational rewiring remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating scaffold targeting, substrate docking, and αG/C-terminal autophosphorylation states","Endogenous signals controlling CK1α abundance and activity in each pathway incompletely defined","Isoform-specific (α vs δ/ε) contributions to many substrates unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,5,6,16,17,22,24,25]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[3,24,30,38]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,18]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[37]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13,14,37]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[6,28,39]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[21,29,33]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,5,21,22,24]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[6,28,39]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15,16]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[4,40,41,42]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2,9,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14]}],"complexes":["β-catenin destruction complex","necrosome","MDM2-CK1α complex","Star-PAP complex"],"partners":["MDM2","AXIN1","FAM83D","FAM83F","PER2","CRBN","RIPK3","PTEN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P48729","full_name":"Casein kinase I isoform alpha","aliases":["CK1"],"length_aa":337,"mass_kda":38.9,"function":"Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (PubMed:11955436, PubMed:1409656, PubMed:18305108, PubMed:23902688). It can phosphorylate a large number of proteins (PubMed:11955436, PubMed:1409656, PubMed:18305108, PubMed:23902688). Participates in Wnt signaling (PubMed:11955436). Phosphorylates CTNNB1 at 'Ser-45' (PubMed:11955436). May phosphorylate PER1 and PER2 (By similarity). May play a role in segregating chromosomes during mitosis (PubMed:1409656). May play a role in keratin cytoskeleton disassembly and thereby, it may regulate epithelial cell migration (PubMed:23902688). Acts as a positive regulator of mTORC1 and mTORC2 signaling in response to nutrients by mediating phosphorylation of DEPTOR inhibitor (PubMed:22017875, PubMed:22017877). Acts as an inhibitor of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (By similarity)","subcellular_location":"Cytoplasm; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Chromosome, centromere, kinetochore; Nucleus speckle; Cytoplasm, cytoskeleton, cilium basal body; Cytoplasm, cytoskeleton, spindle","url":"https://www.uniprot.org/uniprotkb/P48729/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CSNK1A1","classification":"Common Essential","n_dependent_lines":979,"n_total_lines":1208,"dependency_fraction":0.8104304635761589},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000113712","cell_line_id":"CID001161","localizations":[{"compartment":"centrosome","grade":3},{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3},{"compartment":"membrane","grade":2},{"compartment":"cell_contact","grade":1}],"interactors":[{"gene":"SEC13","stoichiometry":10.0},{"gene":"SEC16A","stoichiometry":10.0},{"gene":"GAPVD1","stoichiometry":10.0},{"gene":"XRCC4","stoichiometry":4.0},{"gene":"RASAL2","stoichiometry":4.0},{"gene":"DBR1","stoichiometry":4.0},{"gene":"FAM83H","stoichiometry":4.0},{"gene":"FAM83G","stoichiometry":4.0},{"gene":"HMMR","stoichiometry":4.0},{"gene":"COPA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001161","total_profiled":1310},"omim":[{"mim_id":"621522","title":"SCAFFOLDING CK1-ANCHORING PROTEIN F; SACK1F","url":"https://www.omim.org/entry/621522"},{"mim_id":"621521","title":"SCAFFOLDING CK1-ANCHORING PROTEIN E; SACK1E","url":"https://www.omim.org/entry/621521"},{"mim_id":"621520","title":"SCAFFOLDING CK1-ANCHORING PROTEIN C; SACK1C","url":"https://www.omim.org/entry/621520"},{"mim_id":"621519","title":"SCAFFOLDING CK1-ANCHORING PROTEIN B; SACK1B","url":"https://www.omim.org/entry/621519"},{"mim_id":"621022","title":"SCAFFOLDING CK1-ANCHORING PROTEIN A; SACK1A","url":"https://www.omim.org/entry/621022"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CSNK1A1"},"hgnc":{"alias_symbol":["CK1","CK1a","CK1alpha","CKIa","CKIalpha"],"prev_symbol":[]},"alphafold":{"accession":"P48729","domains":[{"cath_id":"3.30.200.20","chopping":"18-32_44-90","consensus_level":"high","plddt":94.3011,"start":18,"end":90},{"cath_id":"1.10.510.10","chopping":"94-287","consensus_level":"high","plddt":97.7506,"start":94,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P48729","model_url":"https://alphafold.ebi.ac.uk/files/AF-P48729-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P48729-F1-predicted_aligned_error_v6.png","plddt_mean":91.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSNK1A1","jax_strain_url":"https://www.jax.org/strain/search?query=CSNK1A1"},"sequence":{"accession":"P48729","fasta_url":"https://rest.uniprot.org/uniprotkb/P48729.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P48729/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P48729"}},"corpus_meta":[{"pmid":"20048001","id":"PMC_20048001","title":"A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP).","date":"2010","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/20048001","citation_count":1230,"is_preprint":false},{"pmid":"26131937","id":"PMC_26131937","title":"Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26131937","citation_count":708,"is_preprint":false},{"pmid":"26909574","id":"PMC_26909574","title":"Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26909574","citation_count":481,"is_preprint":false},{"pmid":"24904820","id":"PMC_24904820","title":"The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24904820","citation_count":231,"is_preprint":false},{"pmid":"14710188","id":"PMC_14710188","title":"D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a.","date":"2004","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/14710188","citation_count":230,"is_preprint":false},{"pmid":"20696890","id":"PMC_20696890","title":"Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20696890","citation_count":210,"is_preprint":false},{"pmid":"21179498","id":"PMC_21179498","title":"High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase.","date":"2010","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/21179498","citation_count":202,"is_preprint":false},{"pmid":"21695114","id":"PMC_21695114","title":"Sonic Hedgehog dependent phosphorylation by CK1α and GRK2 is required for ciliary accumulation and activation of smoothened.","date":"2011","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/21695114","citation_count":180,"is_preprint":false},{"pmid":"21331045","id":"PMC_21331045","title":"CKIα ablation highlights a critical role for p53 in invasiveness control.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21331045","citation_count":162,"is_preprint":false},{"pmid":"17244647","id":"PMC_17244647","title":"Wnt-5a induces Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17244647","citation_count":152,"is_preprint":false},{"pmid":"15121840","id":"PMC_15121840","title":"A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15121840","citation_count":151,"is_preprint":false},{"pmid":"29483652","id":"PMC_29483652","title":"Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63.","date":"2018","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29483652","citation_count":133,"is_preprint":false},{"pmid":"16061179","id":"PMC_16061179","title":"Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16061179","citation_count":129,"is_preprint":false},{"pmid":"32111827","id":"PMC_32111827","title":"Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32111827","citation_count":126,"is_preprint":false},{"pmid":"20577972","id":"PMC_20577972","title":"Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.","date":"2010","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20577972","citation_count":123,"is_preprint":false},{"pmid":"29593330","id":"PMC_29593330","title":"CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29593330","citation_count":120,"is_preprint":false},{"pmid":"10606744","id":"PMC_10606744","title":"Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10606744","citation_count":118,"is_preprint":false},{"pmid":"16326393","id":"PMC_16326393","title":"Phosphorylation by double-time/CKIepsilon and CKIalpha targets cubitus interruptus for Slimb/beta-TRCP-mediated proteolytic processing.","date":"2005","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/16326393","citation_count":118,"is_preprint":false},{"pmid":"22415086","id":"PMC_22415086","title":"Protein kinase CK1α regulates erythrocyte survival.","date":"2012","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22415086","citation_count":113,"is_preprint":false},{"pmid":"16186692","id":"PMC_16186692","title":"The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development.","date":"2005","source":"Onkologie","url":"https://pubmed.ncbi.nlm.nih.gov/16186692","citation_count":102,"is_preprint":false},{"pmid":"24592867","id":"PMC_24592867","title":"Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24592867","citation_count":92,"is_preprint":false},{"pmid":"18203806","id":"PMC_18203806","title":"Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.","date":"2008","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/18203806","citation_count":89,"is_preprint":false},{"pmid":"19759023","id":"PMC_19759023","title":"CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19759023","citation_count":88,"is_preprint":false},{"pmid":"24616378","id":"PMC_24616378","title":"Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24616378","citation_count":85,"is_preprint":false},{"pmid":"20305697","id":"PMC_20305697","title":"Role of CK1 in GSK3beta-mediated phosphorylation and degradation of snail.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20305697","citation_count":74,"is_preprint":false},{"pmid":"21606194","id":"PMC_21606194","title":"Coordinated action of CK1 isoforms in canonical Wnt signaling.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21606194","citation_count":74,"is_preprint":false},{"pmid":"11161704","id":"PMC_11161704","title":"Catalytic activity of protein kinase CK1 delta (casein kinase 1delta) is essential for its normal subcellular localization.","date":"2001","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11161704","citation_count":67,"is_preprint":false},{"pmid":"33306089","id":"PMC_33306089","title":"Functions and regulation of the serine/threonine protein kinase CK1 family: moving beyond promiscuity.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33306089","citation_count":66,"is_preprint":false},{"pmid":"31376410","id":"PMC_31376410","title":"Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31376410","citation_count":64,"is_preprint":false},{"pmid":"24317512","id":"PMC_24317512","title":"CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24317512","citation_count":60,"is_preprint":false},{"pmid":"20215527","id":"PMC_20215527","title":"Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20215527","citation_count":60,"is_preprint":false},{"pmid":"33261128","id":"PMC_33261128","title":"Targeting Casein Kinase 1 (CK1) in Hematological Cancers.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33261128","citation_count":59,"is_preprint":false},{"pmid":"28943242","id":"PMC_28943242","title":"CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic Tissue.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/28943242","citation_count":58,"is_preprint":false},{"pmid":"18246126","id":"PMC_18246126","title":"PML enhances the regulation of p53 by CK1 in response to DNA damage.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18246126","citation_count":55,"is_preprint":false},{"pmid":"17434749","id":"PMC_17434749","title":"Purification of CK1 by affinity chromatography on immobilised axin.","date":"2007","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/17434749","citation_count":54,"is_preprint":false},{"pmid":"8550544","id":"PMC_8550544","title":"Induced release of cell surface protein kinase yields CK1- and CK2-like enzymes in tandem.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8550544","citation_count":53,"is_preprint":false},{"pmid":"10095790","id":"PMC_10095790","title":"Optimal sequences for non-phosphate-directed phosphorylation by protein kinase CK1 (casein kinase-1)--a re-evaluation.","date":"1999","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10095790","citation_count":50,"is_preprint":false},{"pmid":"31932442","id":"PMC_31932442","title":"CK1α, CK1δ, and CK1ε are necrosome components which phosphorylate serine 227 of human RIPK3 to activate necroptosis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31932442","citation_count":49,"is_preprint":false},{"pmid":"29871876","id":"PMC_29871876","title":"The FAM83 family of proteins: from pseudo-PLDs to anchors for CK1 isoforms.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/29871876","citation_count":48,"is_preprint":false},{"pmid":"18305108","id":"PMC_18305108","title":"CKIalpha is associated with and phosphorylates star-PAP and is also required for expression of select star-PAP target messenger RNAs.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18305108","citation_count":46,"is_preprint":false},{"pmid":"23438105","id":"PMC_23438105","title":"Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23438105","citation_count":46,"is_preprint":false},{"pmid":"28236970","id":"PMC_28236970","title":"CK1 in Developmental Signaling: Hedgehog and Wnt.","date":"2016","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28236970","citation_count":45,"is_preprint":false},{"pmid":"32965059","id":"PMC_32965059","title":"RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer.","date":"2020","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/32965059","citation_count":43,"is_preprint":false},{"pmid":"25628462","id":"PMC_25628462","title":"Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25628462","citation_count":43,"is_preprint":false},{"pmid":"12210746","id":"PMC_12210746","title":"Biochemical and cellular characteristics of the four splice variants of protein kinase CK1alpha from zebrafish (Danio rerio).","date":"2002","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12210746","citation_count":43,"is_preprint":false},{"pmid":"29954751","id":"PMC_29954751","title":"CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29954751","citation_count":42,"is_preprint":false},{"pmid":"24710172","id":"PMC_24710172","title":"The RNA helicase FRH is an ATP-dependent regulator of CK1a in the circadian clock of Neurospora crassa.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24710172","citation_count":42,"is_preprint":false},{"pmid":"15747065","id":"PMC_15747065","title":"A second protein kinase CK1-mediated step negatively regulates Wnt signalling by disrupting the lymphocyte enhancer factor-1/beta-catenin complex.","date":"2005","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/15747065","citation_count":42,"is_preprint":false},{"pmid":"28655862","id":"PMC_28655862","title":"Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors.","date":"2017","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28655862","citation_count":42,"is_preprint":false},{"pmid":"37207626","id":"PMC_37207626","title":"PERIOD phosphorylation leads to feedback inhibition of CK1 activity to control circadian period.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37207626","citation_count":41,"is_preprint":false},{"pmid":"17962809","id":"PMC_17962809","title":"Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17962809","citation_count":41,"is_preprint":false},{"pmid":"36898380","id":"PMC_36898380","title":"Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36898380","citation_count":39,"is_preprint":false},{"pmid":"30651631","id":"PMC_30651631","title":"Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30651631","citation_count":39,"is_preprint":false},{"pmid":"26984280","id":"PMC_26984280","title":"The nucleolar protein NIFK promotes cancer progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell proliferation.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26984280","citation_count":39,"is_preprint":false},{"pmid":"24055157","id":"PMC_24055157","title":"CK1 is required for a mitotic checkpoint that delays cytokinesis.","date":"2013","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/24055157","citation_count":38,"is_preprint":false},{"pmid":"15687492","id":"PMC_15687492","title":"Protein kinase CK1alpha regulates mRNA binding by heterogeneous nuclear ribonucleoprotein C in response to physiologic levels of hydrogen peroxide.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15687492","citation_count":38,"is_preprint":false},{"pmid":"31338967","id":"PMC_31338967","title":"FAM83D directs protein kinase CK1α to the mitotic spindle for proper spindle positioning.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31338967","citation_count":37,"is_preprint":false},{"pmid":"35810166","id":"PMC_35810166","title":"Decoupling PER phosphorylation, stability and rhythmic expression from circadian clock function by abolishing PER-CK1 interaction.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35810166","citation_count":37,"is_preprint":false},{"pmid":"25512501","id":"PMC_25512501","title":"Hedgehog-induced phosphorylation by CK1 sustains the activity of Ci/Gli activator.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25512501","citation_count":37,"is_preprint":false},{"pmid":"17910481","id":"PMC_17910481","title":"Chemical dissection of the APC Repeat 3 multistep phosphorylation by the concerted action of protein kinases CK1 and GSK3.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17910481","citation_count":37,"is_preprint":false},{"pmid":"31400711","id":"PMC_31400711","title":"Small molecule modulators targeting protein kinase CK1 and CK2.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31400711","citation_count":36,"is_preprint":false},{"pmid":"38228616","id":"PMC_38228616","title":"Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38228616","citation_count":36,"is_preprint":false},{"pmid":"28969692","id":"PMC_28969692","title":"Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28969692","citation_count":36,"is_preprint":false},{"pmid":"18799313","id":"PMC_18799313","title":"Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18799313","citation_count":36,"is_preprint":false},{"pmid":"17172446","id":"PMC_17172446","title":"The first armadillo repeat is involved in the recognition and regulation of beta-catenin phosphorylation by protein kinase CK1.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17172446","citation_count":35,"is_preprint":false},{"pmid":"22489878","id":"PMC_22489878","title":"Aspergillus nidulans CkiA is an essential casein kinase I required for delivery of amino acid transporters to the plasma membrane.","date":"2012","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/22489878","citation_count":34,"is_preprint":false},{"pmid":"24290981","id":"PMC_24290981","title":"Control of epithelial cell migration and invasion by the IKKβ- and CK1α-mediated degradation of RAPGEF2.","date":"2013","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/24290981","citation_count":34,"is_preprint":false},{"pmid":"8050587","id":"PMC_8050587","title":"Cloning and chromosomal localization of the gene coding for human protein kinase CK1.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8050587","citation_count":34,"is_preprint":false},{"pmid":"19538290","id":"PMC_19538290","title":"Differential phosphorylation of occludin and tricellulin by CK2 and CK1.","date":"2009","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19538290","citation_count":34,"is_preprint":false},{"pmid":"22235331","id":"PMC_22235331","title":"Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22235331","citation_count":34,"is_preprint":false},{"pmid":"28878021","id":"PMC_28878021","title":"CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28878021","citation_count":33,"is_preprint":false},{"pmid":"19752022","id":"PMC_19752022","title":"Regulation of dynein-driven microtubule sliding by the axonemal protein kinase CK1 in Chlamydomonas flagella.","date":"2009","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19752022","citation_count":33,"is_preprint":false},{"pmid":"20041275","id":"PMC_20041275","title":"Isoform specific phosphorylation of p53 by protein kinase CK1.","date":"2009","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/20041275","citation_count":33,"is_preprint":false},{"pmid":"28099937","id":"PMC_28099937","title":"Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28099937","citation_count":33,"is_preprint":false},{"pmid":"19115251","id":"PMC_19115251","title":"Autophosphorylation of carboxy-terminal residues inhibits the activity of protein kinase CK1alpha.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19115251","citation_count":30,"is_preprint":false},{"pmid":"18419275","id":"PMC_18419275","title":"Posttranslational regulation of Neurospora circadian clock by CK1a-dependent phosphorylation.","date":"2007","source":"Cold Spring Harbor symposia on quantitative biology","url":"https://pubmed.ncbi.nlm.nih.gov/18419275","citation_count":28,"is_preprint":false},{"pmid":"15975091","id":"PMC_15975091","title":"Generation of protein kinase Ck1alpha mutants which discriminate between canonical and non-canonical substrates.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15975091","citation_count":28,"is_preprint":false},{"pmid":"35279748","id":"PMC_35279748","title":"S100A16 promotes acute kidney injury by activating HRD1-induced ubiquitination and degradation of GSK3β and CK1α.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35279748","citation_count":28,"is_preprint":false},{"pmid":"23354688","id":"PMC_23354688","title":"Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23354688","citation_count":28,"is_preprint":false},{"pmid":"35353987","id":"PMC_35353987","title":"Kinase domain autophosphorylation rewires the activity and substrate specificity of CK1 enzymes.","date":"2022","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/35353987","citation_count":26,"is_preprint":false},{"pmid":"11004513","id":"PMC_11004513","title":"Human CKIalpha(L) and CKIalpha(S) are encoded by both 2.4- and 4. 2-kb transcripts, the longer containing multiple RNA-destablising elements.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11004513","citation_count":26,"is_preprint":false},{"pmid":"24762815","id":"PMC_24762815","title":"The tumor suppressor APC differentially regulates multiple β-catenins through the function of axin and CKIα during C. elegans asymmetric stem cell divisions.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24762815","citation_count":26,"is_preprint":false},{"pmid":"15811523","id":"PMC_15811523","title":"Characterization of two T. gondii CK1 isoforms.","date":"2005","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/15811523","citation_count":26,"is_preprint":false},{"pmid":"28945225","id":"PMC_28945225","title":"Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28945225","citation_count":25,"is_preprint":false},{"pmid":"31123604","id":"PMC_31123604","title":"Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma.","date":"2019","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31123604","citation_count":25,"is_preprint":false},{"pmid":"30487124","id":"PMC_30487124","title":"A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30487124","citation_count":25,"is_preprint":false},{"pmid":"29222110","id":"PMC_29222110","title":"A CK1 FRET biosensor reveals that DDX3X is an essential activator of CK1ε.","date":"2018","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/29222110","citation_count":25,"is_preprint":false},{"pmid":"30373768","id":"PMC_30373768","title":"CK1α Collaborates with DOUBLETIME to Regulate PERIOD Function in the Drosophila Circadian Clock.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30373768","citation_count":25,"is_preprint":false},{"pmid":"29611807","id":"PMC_29611807","title":"CK1/Doubletime activity delays transcription activation in the circadian clock.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29611807","citation_count":25,"is_preprint":false},{"pmid":"18590726","id":"PMC_18590726","title":"Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18590726","citation_count":24,"is_preprint":false},{"pmid":"33918307","id":"PMC_33918307","title":"Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33918307","citation_count":23,"is_preprint":false},{"pmid":"34726688","id":"PMC_34726688","title":"CHMP2B regulates TDP-43 phosphorylation and cytotoxicity independent of autophagy via CK1.","date":"2021","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34726688","citation_count":22,"is_preprint":false},{"pmid":"9022677","id":"PMC_9022677","title":"The recombinant alpha isoform of protein kinase CK1 from Xenopus laevis can phosphorylate tyrosine in synthetic substrates.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9022677","citation_count":22,"is_preprint":false},{"pmid":"18239272","id":"PMC_18239272","title":"A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro.","date":"2008","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/18239272","citation_count":21,"is_preprint":false},{"pmid":"34182774","id":"PMC_34182774","title":"FRQ-CK1 Interaction Underlies Temperature Compensation of the Neurospora Circadian Clock.","date":"2021","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/34182774","citation_count":20,"is_preprint":false},{"pmid":"22916255","id":"PMC_22916255","title":"Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22916255","citation_count":20,"is_preprint":false},{"pmid":"14712927","id":"PMC_14712927","title":"CK1 and GSK3 in the Drosophila and mammalian circadian clock.","date":"2003","source":"Novartis Foundation symposium","url":"https://pubmed.ncbi.nlm.nih.gov/14712927","citation_count":20,"is_preprint":false},{"pmid":"33361109","id":"PMC_33361109","title":"FAM83F regulates canonical Wnt signalling through an interaction with CK1α.","date":"2020","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/33361109","citation_count":18,"is_preprint":false},{"pmid":"38085607","id":"PMC_38085607","title":"Design and Development of IKZF2 and CK1α Dual Degraders.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38085607","citation_count":17,"is_preprint":false},{"pmid":"26688096","id":"PMC_26688096","title":"CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.","date":"2015","source":"The Lancet. Haematology","url":"https://pubmed.ncbi.nlm.nih.gov/26688096","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49485,"output_tokens":10877,"usd":0.155805,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22052,"output_tokens":6897,"usd":0.141343,"stage2_stop_reason":"end_turn"},"total_usd":0.297148,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"Lenalidomide induces ubiquitination and degradation of CK1α by the CRL4(CRBN) E3 ubiquitin ligase (CUL4-RBX1-DDB1-CRBN); haploinsufficiency of CK1α in del(5q) MDS sensitizes cells to this degradation, providing the mechanistic basis for lenalidomide's therapeutic window in del(5q) MDS.\",\n      \"method\": \"Ubiquitination assays, immunoprecipitation, mouse-human CRBN single amino acid swap rescue experiment, mass spectrometry\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods (ubiquitination assay, IP, genetic rescue), replicated across studies, mechanistic conclusion validated in cellulo and in vivo\",\n      \"pmids\": [\"26131937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure (2.45 Å) of DDB1-CRBN bound to lenalidomide and CK1α shows that CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop in the kinase N-lobe; CK1α binding to CRL4(CRBN) is strictly IMiD-dependent.\",\n      \"method\": \"X-ray crystallography, binding assays, mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with functional validation, published in Nature, independently consistent with biochemical data from companion studies\",\n      \"pmids\": [\"26909574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CKIα is a component of the β-catenin destruction complex; conditional ablation of Csnk1a1 in mouse gut triggers massive Wnt/β-catenin activation and concurrent p53 activation; combined loss of CKIα and p53 (or p21) drives invasive carcinoma, establishing CKIα as a tumour suppressor downstream of p53.\",\n      \"method\": \"Conditional knockout (Cre-lox) mouse model, histology, gene expression profiling, epistasis analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with multiple compound knockouts and defined phenotypic readouts, published in Nature\",\n      \"pmids\": [\"21331045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CK1α phosphorylates YAP at Ser381 (after Lats primes it), creating a phosphodegron that recruits SCF(β-TRCP) E3 ubiquitin ligase leading to YAP ubiquitination and degradation; CK1δ/ε are identified as the relevant isoforms for this step.\",\n      \"method\": \"In vitro kinase assay, phospho-specific antibodies, co-immunoprecipitation, ubiquitination assay, mutagenesis\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted phosphorylation cascade in vitro plus mutagenesis of phosphodegron, multiple orthogonal methods\",\n      \"pmids\": [\"20048001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CK1α acts as a clock regulatory kinase that phosphorylates PER1 to stimulate its degradation; siRNA knockdown of CKIα lengthens circadian period; combinatorial knockdown of CKIδ, CKIα and ERK2 dramatically lengthens period, revealing a multi-kinase network for clock robustness.\",\n      \"method\": \"Affinity chromatography/mass spectrometry target identification, siRNA knockdown, circadian reporter assays, chemical inhibition\",\n      \"journal\": \"PLoS Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — target ID by affinity-MS plus functional siRNA validation, single lab, two orthogonal approaches\",\n      \"pmids\": [\"21179498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CK1α phosphorylates the carboxyl-terminal tail of mammalian Smoothened (mSmo) at multiple sites to induce its active conformation and promote ciliary accumulation; Hh signaling recruits CK1α to initiate mSmo phosphorylation, and phosphorylation further increases CK1α/GRK2 binding, forming a positive feedback loop.\",\n      \"method\": \"In vitro kinase assay, phosphorylation-site mutagenesis, co-immunoprecipitation, immunofluorescence, cell-based Hh signaling assays\",\n      \"journal\": \"PLoS Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution plus mutagenesis plus cell-based functional readout, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"21695114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CKIα phosphorylates FADD at Ser194 both in vitro and in vivo; FADD-CKIα association regulates subcellular localization of FADD, with phosphorylated FADD co-localizing with CKIα at spindle poles in metaphase; CKIα inhibition prevents Taxol-induced mitotic arrest and blocks mitogen-induced proliferation.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, immunofluorescence, pharmacological inhibition, splenocyte proliferation assay\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation assay with defined substrate site, co-IP, localization, and functional rescue with phospho-site mutant mice\",\n      \"pmids\": [\"16061179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CK1α phosphorylates FADD downstream of oncogenic KRAS, promoting mitotic entry; deletion of CK1α in KRAS-mutant mice abrogates FADD phosphorylation and suppresses lung cancer development; phosphorylated FADD interacts with PLK1, AURKA, and BUB1 in a CK1α-dependent manner during G2/M.\",\n      \"method\": \"Conditional knockout mouse model, mass spectrometry, immunohistochemistry, in vivo imaging, kinase inhibitor treatment\",\n      \"journal\": \"Science Signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic evidence plus MS substrate identification plus functional phenotype, single lab\",\n      \"pmids\": [\"25628462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CK1α forms a stable complex with MDM2 in undamaged cells; depletion or inhibition of CK1α stabilizes p53 and destabilizes E2F-1, indicating CK1α is a negative regulator of p53 and positive regulator of E2F-1 through the MDM2-CK1α complex.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition (D4476), co-immunoprecipitation of endogenous proteins, western blot\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP of endogenous proteins plus RNAi and chemical inhibition with consistent results, single lab\",\n      \"pmids\": [\"19759023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Csnk1a1 knockdown in AML cells results in decreased Rps6 phosphorylation and increased p53 activity leading to myeloid differentiation; p53-null leukemias are insensitive to Csnk1a1 knockdown, placing CK1α upstream of p53 in a leukemia-survival pathway.\",\n      \"method\": \"shRNA knockdown, in vivo pooled shRNA screen, gene expression profiling, pharmacological inhibition (D4476), flow cytometry\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic screen plus epistasis analysis (p53-null rescue), functional cellular and molecular readouts\",\n      \"pmids\": [\"24616378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CKIα is associated with the nuclear poly(A) polymerase Star-PAP and directly phosphorylates it; CKIα and PIPKIα are both required for expression of a subset of Star-PAP target mRNAs; CKIα activity is PI-4,5-P2-sensitive within the Star-PAP complex.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, qRT-PCR\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation assay plus co-IP plus functional knockdown, single lab\",\n      \"pmids\": [\"18305108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CK1 phosphorylates p53 at Thr18 in vitro; this phosphorylation requires prior phosphorylation of Ser15, establishing a phosphorylation-priming hierarchy at the MDM2-binding domain of p53.\",\n      \"method\": \"In vitro kinase assay with recombinant CK1δ and p53, phospho-site mapping\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution but single lab, single method, no mutagenesis confirmation of functional consequence\",\n      \"pmids\": [\"10606744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CK1α and CK1δ directly phosphorylate p53 preferentially at S20 (not S6); affinity for full-length p53 is ~1000-fold higher than for the N-terminal peptide, implicating a remote docking site mapped to the K221RQK224 loop; CK1γ1 does not phosphorylate p53.\",\n      \"method\": \"In vitro kinase assay with recombinant isoforms, Km determination, mutagenesis of docking loop\",\n      \"journal\": \"Cellular and Molecular Life Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple isoforms plus mutagenesis, single lab\",\n      \"pmids\": [\"20041275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PML enhances CK1-mediated phosphorylation of p53 at Thr18 in response to DNA damage; CK1 interacts with endogenous p53 and PML and this interaction is enhanced by genotoxic stress; PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, protecting p53 from MDM2-mediated degradation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, phospho-specific antibodies, CK1 inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of endogenous proteins plus localization plus functional inhibitor readout, single lab, multiple complementary methods\",\n      \"pmids\": [\"18246126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CK1 phosphorylates NFAT1 specifically at the SRR-1 motif (required for nuclear import); CK1 exists with NFAT1 in a high-molecular-weight complex in resting T cells but dissociates upon activation; a conserved docking motif in NFAT proteins is required for CK1 interaction, and its mutation causes constitutive nuclear localization of NFAT1.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, mutagenesis, nuclear localization imaging\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation plus docking-motif mutagenesis with functional nuclear-localization readout, multiple orthogonal methods\",\n      \"pmids\": [\"15121840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CK1 is the executioner kinase for p63 activation in oocyte DNA-damage quality control; both CHK2 (priming) and CK1 (execution) phosphorylations are required to induce p63's active tetrameric conformation; CK1 inhibition rescues primary oocytes from chemotherapy-induced apoptosis.\",\n      \"method\": \"Biochemical phosphorylation assays, structural analysis of p63 conformational changes, mouse primordial follicle experiments, CK1 inhibitor rescue\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assays, structural data on p63 conformational change, and in vivo rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"29483652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CK1α, CK1δ, and CK1ε are necrosome components that directly phosphorylate RIPK3 at Ser227 to activate necroptosis; this interaction depends on RIPK3 kinase activity; a RIPK3 CK1-recognition-motif mutant fails to be phosphorylated at S227, does not bind MLKL, and cannot activate necroptosis.\",\n      \"method\": \"Tandem immunoprecipitation, in vitro kinase assay, CK1 loss-of-function, RIPK3 recognition-motif mutagenesis, necroptosis assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro phosphorylation assay plus genetic loss-of-function plus rescue mutagenesis with functional cell death readout, multiple orthogonal methods\",\n      \"pmids\": [\"31932442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CSNK1a1 directly binds and phosphorylates PRMT1 to control its genomic targeting; loss of CSNK1a1 in epidermal progenitors (mouse and human) abolishes progenitor self-renewal and leads to premature differentiation through derepression of GRHL3.\",\n      \"method\": \"Mass spectrometry (PRMT1 interactome), co-immunoprecipitation, in vitro kinase assay, conditional mouse knockout, human mosaic epidermis in vivo regeneration\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — MS-identified interaction confirmed by co-IP and in vitro phosphorylation, plus in vivo genetic validation in mouse and human tissue\",\n      \"pmids\": [\"28943242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CK1α suppresses NSCLC tumour growth by binding the C-terminal tail of PTEN and enhancing PTEN stability and activity by competitively antagonizing NEDD4-1-induced polyubiquitination and abrogating PTEN phosphorylation, thereby inhibiting AKT and activating FOXO3a-induced Atg7 transcription and autophagy.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, in vitro binding assay, CK1α knockdown/overexpression, xenograft models\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus ubiquitination assay plus xenograft functional validation, multiple orthogonal methods replicated in vivo\",\n      \"pmids\": [\"29593330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CK1α phosphorylates CBX4 at T437, which facilitates CBX4 ubiquitination at K178 and K280 and subsequent CHIP-mediated degradation; TNFα reduces CK1α-mediated CBX4 phosphorylation; CK1α suppresses osteosarcoma cell migration and invasion through CBX4 inhibition.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, ubiquitination assay, phospho-site mutagenesis, cell migration/invasion assays\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with phospho-site mutagenesis plus ubiquitination assay plus functional cell biology readout, multiple orthogonal methods\",\n      \"pmids\": [\"32111827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CK1α phosphorylates RAPGEF2 in response to pro-motility factors, together with IKKβ, leading to proteasomal degradation via SCF(βTrCP); failure to degrade RAPGEF2 sustains Rap1 activity and inhibits HGF-induced cell migration.\",\n      \"method\": \"Phosphorylation assays, co-immunoprecipitation, degradation-resistant mutant expression, cell migration assays, xenograft metastasis model\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation assay plus co-IP plus functional mutant rescue plus in vivo metastasis, single lab\",\n      \"pmids\": [\"24290981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In the canonical Wnt pathway, CK1α associates with the LRP5/6/p120-catenin complex after Wnt3a stimulation in a CK1ε-dependent manner and within a complex with axin; CK1α participates in the release of p120-catenin from the LRP5/6 complex to activate downstream signalling.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, Wnt reporter assays, sequential epistasis analysis\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus siRNA epistasis with reporter assay readout, single lab, multiple complementary approaches\",\n      \"pmids\": [\"21606194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CK1 phosphorylates Ci (Drosophila Gli) at three PKA/GSK3-primed serine clusters, creating Slimb/β-TRCP binding sites that cooperatively recruit SCF(Slimb) ubiquitin ligase for Ci proteolytic processing; CKIα and DBT/CKIε act in conjunction for this step.\",\n      \"method\": \"In vitro kinase assay, mutagenesis of phosphorylation clusters, Slimb binding assay, Drosophila in vivo epistasis\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution plus mutagenesis plus in vivo Drosophila genetic validation, multiple orthogonal methods\",\n      \"pmids\": [\"16326393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CK1 phosphorylates Ci/Gli activator isoforms at multiple Ser/Thr-rich degrons downstream of Costal2 and Sufu to inhibit HIB (Cullin3 E3 ligase substrate receptor)-mediated Ci(A) degradation, sustaining Hh pathway activity; Gli(A) is similarly regulated in vertebrates.\",\n      \"method\": \"In vitro kinase assay, mutagenesis, co-immunoprecipitation, Drosophila genetics, mammalian cell Hh reporter assays\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation plus mutagenesis plus in vivo Drosophila and mammalian cell evidence, multiple orthogonal methods\",\n      \"pmids\": [\"25512501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CK1 phosphorylates β-catenin at Ser45; the first armadillo repeat of β-catenin is required for high-affinity CK1 recognition (removing it raises Km ~50-fold); α-catenin binding to β-catenin's N-terminal region prevents CK1-mediated Ser45 phosphorylation.\",\n      \"method\": \"In vitro kinase assay with deletion mutants, Km determination, competition assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with systematic mutants defining docking determinants, single lab, multiple substrate variants tested\",\n      \"pmids\": [\"17172446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CK1 initiates phosphorylation of APC repeat-3 (R3) at S1510 and S1505 via non-canonical determinants; phospho-S1505 primes GSK3 phosphorylation of S1501; phospho-S1501 in turn triggers hierarchical CK1 phosphorylation of S1504 and S1507, completing a six-step cascade required for β-catenin degradation.\",\n      \"method\": \"In vitro kinase assay with variably phosphorylated peptides, Edman degradation phospho-site mapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — detailed in vitro reconstitution of the phosphorylation cascade, single lab, systematic peptide analysis\",\n      \"pmids\": [\"17910481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CK1 directly phosphorylates LEF-1 and disrupts the LEF-1/β-catenin complex (without impairing LEF-1/DNA binding); this requires co-phosphorylation of β-catenin; CK1-dependent phosphorylation inhibits LEF-1/β-catenin transcriptional activity, establishing CK1 as a second-level negative regulator of canonical Wnt signalling.\",\n      \"method\": \"In vitro kinase assay, GST pulldown, electrophoretic mobility shift assay, luciferase reporter assay\",\n      \"journal\": \"Cellular and Molecular Life Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation assay plus protein interaction disruption assay plus reporter readout, single lab\",\n      \"pmids\": [\"15747065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CK1α phosphorylates hnRNP-C at Ser240 and Ser225-228 in response to physiological H2O2; phosphorylation at CK1α sites causes 14–500-fold decrease in hnRNP-C RNA-binding affinity, as shown by phosphomimetic mutations.\",\n      \"method\": \"Kinase purification and identification by tandem MS, in vitro kinase assay, co-immunoprecipitation, fluorescence RNA binding assay with phosphomimetic mutants\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — kinase identified by MS purification, in vitro phosphorylation confirmed, functional consequence demonstrated by RNA binding assay with phosphomimetics\",\n      \"pmids\": [\"15687492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FAM83D recruits CK1α to the mitotic spindle; cells lacking FAM83D or carrying CK1α-binding-deficient FAM83DF283A/F283A knockin mutations display spindle positioning defects and prolonged mitosis; artificial re-delivery of CK1α to the spindle rescues these defects.\",\n      \"method\": \"CRISPR/Cas9 knockin, live-cell imaging, immunofluorescence, FAM83D knockout, spindle positioning assay\",\n      \"journal\": \"EMBO Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockin plus knockout with functional rescue, two orthogonal localization approaches, specific mechanistic pathway placement\",\n      \"pmids\": [\"31338967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Truncating RNF43 cancer mutations trap CK1 at the plasma membrane by disrupting a ubiquitin-independent suppressor function of the RNF43 cytosolic tail, thereby preventing β-catenin turnover and driving ligand-independent Wnt target gene transcription.\",\n      \"method\": \"Gene editing of human colon stem cells, co-immunoprecipitation, luciferase reporter assay, proximity ligation assay\",\n      \"journal\": \"EMBO Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR gene editing plus co-IP plus reporter assay, single lab, multiple approaches\",\n      \"pmids\": [\"32965059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CK1α autophosphorylates its own C-terminal residues (last four Ser/Thr); this autophosphorylation inhibits catalytic activity; lambda phosphatase treatment activates CK1α by 80–100%, and re-autophosphorylation re-inhibits it, establishing autophosphorylation as a regulatory mechanism.\",\n      \"method\": \"Mass spectrometry of autophosphorylation sites, site-directed mutagenesis to Ala, lambda phosphatase treatment, in vitro kinase assay\",\n      \"journal\": \"Journal of Cellular Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS site identification plus mutagenesis plus phosphatase activation/re-inhibition cycle, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"19115251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CK1 (alpha, delta, epsilon isoforms) binds axin and can be purified by affinity chromatography on an immobilised axin fragment (residues 495–684); the purified enzymes retain high kinase activity, confirming a direct physical CK1α-axin interaction.\",\n      \"method\": \"Affinity chromatography, kinase activity assay\",\n      \"journal\": \"Protein Expression and Purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct binding demonstrated by affinity chromatography, replicated with two different matrix formats, limited to physical interaction without full mechanistic context\",\n      \"pmids\": [\"17434749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Oncogenic RAS elevates CK1α activity to phosphorylate FOXO4 at Ser265/268, triggering its proteasomal degradation; this is partially primed by AKT effectors of RAS signalling; dual inhibition of CK1α and the proteasome synergistically inhibits RAS-mutant cancer cell growth.\",\n      \"method\": \"In vitro kinase assay, phospho-site mutagenesis, CK1α inhibition, FOXO4 stability assays, cell viability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with phospho-site mutagenesis plus functional cell-biology readout, single lab\",\n      \"pmids\": [\"28945225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAM83F is farnesylated and interacts with CK1α at the plasma membrane; this interaction is essential for FAM83F-mediated Wnt pathway activation; a farnesyl-deficient FAM83F knockin redirects the FAM83F-CK1α complex away from the plasma membrane and attenuates Wnt signalling.\",\n      \"method\": \"Co-immunoprecipitation, CRISPR knockin of farnesyl-deficient mutant, Wnt reporter assay, Xenopus axis duplication assay\",\n      \"journal\": \"Life Science Alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus CRISPR knockin with Wnt reporter and Xenopus functional assay, single lab, multiple complementary methods\",\n      \"pmids\": [\"33361109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Decreased CK1α abundance in WNT-driven colorectal tumours (relative to normal tissue) enhances cellular sensitivity to CK1α activators; the small-molecule CK1α activator SSTC3 inhibits CRC xenograft growth; knockdown of CK1α increases sensitivity to SSTC3.\",\n      \"method\": \"Xenograft mouse models, CK1α knockdown, CK1α activator SSTC3 treatment, patient-derived xenograft\",\n      \"journal\": \"Science Signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo xenograft with genetic validation (CK1α knockdown), single lab, functional pharmacology readout\",\n      \"pmids\": [\"28655862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CK1 phosphorylates RhoB specifically at Ser185 in vitro and in cells; phosphorylation by CK1 inhibits RhoB, and CK1 inhibition activates RhoB-dependent actin stress fiber formation and EGF receptor stabilization; RhoA and RhoC are not phosphorylated by CK1.\",\n      \"method\": \"In vitro kinase assay, mass spectrometry phospho-site mapping, site-directed mutagenesis, CK1 inhibitors, immunofluorescence\",\n      \"journal\": \"Experimental Cell Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with MS-confirmed site plus mutagenesis plus functional cell biology, single lab\",\n      \"pmids\": [\"18590726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CK1 phosphorylates PKD2 at Ser244 in response to CCK2R activation; this phosphorylation blocks nuclear export of active PKD2 by preventing Crm-1 interaction, and is prerequisite for efficient phosphorylation of the nuclear PKD2 substrate HDAC7.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, subcellular fractionation, nuclear export inhibition, mutagenesis\",\n      \"journal\": \"EMBO Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus functional nuclear-localization and substrate readout, single lab\",\n      \"pmids\": [\"17962809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The 'L' insert (exon L, 28 aa in catalytic domain) of CK1αL acts as a nuclear localization signal; CK1αL concentrates in the nucleus while CK1α is predominantly cytoplasmic; the L insert increases Km for ATP ~2-fold, decreases CKI-7 sensitivity, and accelerates protein turnover (half-life 100 min vs. 400 min for CK1α).\",\n      \"method\": \"Splice variant expression in Cos-7 cells, immunofluorescence, in vitro kinase assay, protein stability assay\",\n      \"journal\": \"Journal of Cellular Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments plus biochemical characterization, single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"12210746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Autophosphorylation of a conserved threonine (T220 equivalent) in the αG helix of CK1 alters the conformation of the substrate binding cleft, decreasing activity toward most substrates while increasing it toward specific high-affinity substrates; disrupting T220 autophosphorylation rewires CK1 signalling in S. pombe (confirmed by quantitative phosphoproteomics).\",\n      \"method\": \"Crystal structure of autophosphorylated CK1, molecular dynamics simulation, in vitro kinase assay, mutagenesis, quantitative phosphoproteomics\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus MD simulations plus mutagenesis plus quantitative phosphoproteomics, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"35353987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CK1 transmits the signal to stall cytokinesis in a mitotic checkpoint by phosphopriming the SPB scaffold Sid4 for Dma1-mediated ubiquitination; CK1 accumulates at spindle pole bodies during mitotic arrest and stably associates with SPB components including Sid4.\",\n      \"method\": \"Yeast genetics, co-immunoprecipitation, kinase assay, SPB localization by fluorescence microscopy\",\n      \"journal\": \"Current Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis plus SPB localization plus kinase assay in fission yeast, single lab\",\n      \"pmids\": [\"24055157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mutation of PER2 residues essential for CK1 interaction abolishes PER phosphorylation and CLOCK hyperphosphorylation in cells and mice, resulting in PER stabilization and arrhythmic PER abundance; mice show robust short-period locomotor rhythms despite low-amplitude molecular rhythms, demonstrating PER acts as CK1 scaffold.\",\n      \"method\": \"Site-directed mutagenesis, CRISPR knock-in mice, circadian locomotor analysis, western blot for phosphorylation\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutagenesis in cells plus knock-in mouse model with both molecular and behavioural readouts, multiple orthogonal approaches\",\n      \"pmids\": [\"35810166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The phosphorylated FASP region of PER2 directly docks into conserved anion-binding sites near the CK1δ active site to inhibit CK1 activity (product inhibition); crystal structures with molecular dynamics simulations reveal the pFASP-CK1δ interface; limiting FASP phosphorylation reduces product inhibition, decreasing PER2 stability and shortening circadian period.\",\n      \"method\": \"Co-crystal structure of pFASP-CK1δ, molecular dynamics simulations, site-directed mutagenesis, circadian period assay in human cells\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — co-crystal structure plus MD simulations plus mutagenesis plus functional period assay, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"37207626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CK1α collaborates with DBT/CK1δ in the Drosophila clock: CK1α promotes PER nuclear localization by antagonizing DBT-dependent inhibition of nuclear translocation; once in the nucleus, CK1α enhances DBT-dependent PER phosphorylation and degradation.\",\n      \"method\": \"Drosophila genetics (knockdown/overexpression), locomotor rhythm analysis, nuclear/cytoplasmic fractionation, phosphorylation assays\",\n      \"journal\": \"Journal of Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Drosophila genetic analysis with localization and phosphorylation readouts, single lab\",\n      \"pmids\": [\"30373768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SJ3149, a selective CK1α degrader developed through structure-guided SAR around CRBN ligands, shows broad antiproliferative activity correlated with MDM2 inhibitor Nutlin-3a response across 115 cancer cell lines; co-crystal structure of SJ3149 with CK1α+CRBN+DDB1 explains improved degradation properties.\",\n      \"method\": \"Structure-guided medicinal chemistry, co-crystal structure, proteomics, PRISM screen, cell viability panel\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — co-crystal structure plus PRISM screen correlative evidence, single study, mechanistic link to p53 inferred from correlation with Nutlin-3a\",\n      \"pmids\": [\"38228616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CK1α ablation in keratinocytes stabilises both β-catenin and p53; epidermal hyperpigmentation following CK1α loss requires p53-dependent upregulation of KitL (Kit ligand); co-ablation of CK1α and p53 fails to induce hyperpigmentation, and KitL/Kit pathway inhibition abrogates it.\",\n      \"method\": \"Conditional knockout mice (K14-Cre-ERT2), double knockout (CK1α/p53), transcriptome analysis, antibody/inhibitor rescue experiments\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional single and double knockouts with molecular and pharmacological rescue, multiple orthogonal readouts\",\n      \"pmids\": [\"28878021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Reduced Csnk1a1 abundance downstream of DNA damage activates Wnt/β-catenin signalling in mouse embryonic stem cells in a p53-independent manner, limiting DNA-damage-induced apoptosis; this places CK1α as an inhibitor of β-catenin whose loss links DNA damage to Wnt activation.\",\n      \"method\": \"RNAi screen, transcriptomics, phosphoproteomics, gene deletion (p53 KO), Wnt reporter assay\",\n      \"journal\": \"Science Signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systems-biology screen plus genetic validation (p53-independent Wnt activation), multiple data types, single lab\",\n      \"pmids\": [\"23354688\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CK1α (CSNK1A1) is a constitutively active, autophosphorylation-regulated serine/threonine kinase that acts at multiple nodes in Wnt/β-catenin (phosphorylating β-catenin Ser45, APC, LEF-1, axin-bound complexes), Hedgehog (phosphorylating Smoothened and Ci/Gli), p53 (phosphorylating p53 Thr18/Ser20 and forming a stable MDM2-CK1α complex), YAP (creating a phosphodegron for SCF-βTrCP), FADD/RIPK3 (necroptosis), NFAT1, FOXO, PER (circadian clock), PRMT1 (epidermal progenitor maintenance), and multiple other pathways; its subcellular targeting is controlled by scaffold proteins—notably FAM83D at the mitotic spindle—while its activity is regulated by C-terminal autophosphorylation and, pathologically, by IMiD-induced CRL4(CRBN)-mediated degradation that underlies lenalidomide efficacy in del(5q) MDS.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CK1\\u03b1 (CSNK1A1) is a constitutively active serine/threonine kinase that functions as a hierarchical, priming-dependent regulator of protein stability and signalling across the Wnt/\\u03b2-catenin, Hedgehog, p53, Hippo (YAP), circadian, and cell-death pathways [#2, #3, #22, #16]. A recurring theme is that CK1\\u03b1 phosphorylation creates phosphodegrons that license SCF(\\u03b2-TrCP)/Slimb- or other E3-mediated ubiquitination and degradation of its substrates: it primes/completes \\u03b2-catenin destruction-complex turnover by phosphorylating \\u03b2-catenin at Ser45 and APC repeat-3 in a multi-step cascade [#24, #25], phosphorylates YAP Ser381 to recruit SCF(\\u03b2-TRCP) [#3], phosphorylates Ci/Gli to direct SCF(Slimb) processing [#22], and phosphorylates PER1/PER2 for clock-protein degradation [#4, #40]. In vivo, CK1\\u03b1 acts as a tumour suppressor in the gut, where its loss triggers concurrent Wnt and p53 activation and, when combined with p53 loss, drives invasive carcinoma [#2]; it also restrains p53 through a stable MDM2\\u2013CK1\\u03b1 complex and direct phosphorylation of the p53 N-terminus [#8, #11, #12]. CK1\\u03b1 additionally executes apoptotic and necroptotic programs by activating p63 and by phosphorylating RIPK3 at Ser227 within the necrosome [#15, #16]. Its catalytic output is autoregulated: C-terminal autophosphorylation inhibits activity, while autophosphorylation of a conserved \\u03b1G-helix threonine remodels the substrate cleft to rewire substrate selectivity [#30, #38]. Substrate and spatial specificity are imposed by scaffold/docking partners\\u2014axin, FAM83D at the mitotic spindle, FAM83F at the plasma membrane, and PER as a clock scaffold\\u2014that localize the kinase to defined complexes [#31, #28, #33, #40]. Pharmacologically, IMiDs such as lenalidomide convert CK1\\u03b1 into a neosubstrate of the CRL4(CRBN) E3 ligase via a CRBN/lenalidomide-formed interface engaging the CK1\\u03b1 kinase N-lobe, and CK1\\u03b1 haploinsufficiency in del(5q) MDS underlies the therapeutic window of this degradation [#0, #1].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that CK1 phosphorylates the p53 N-terminal MDM2-binding domain in a priming-dependent manner, introducing CK1 as a regulator of the p53\\u2013MDM2 axis.\",\n      \"evidence\": \"In vitro kinase assay with recombinant CK1\\u03b4 and p53, phospho-site mapping\",\n      \"pmids\": [\"10606744\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Used CK1\\u03b4, not CK1\\u03b1, in a peptide context\", \"No mutagenesis confirming the functional consequence in cells\", \"Did not address docking determinants on full-length p53\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed CK1 controls NFAT1 nuclear import through SRR-1 phosphorylation and a docking-motif-dependent association, defining CK1 as a gatekeeper of NFAT subcellular localization.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, docking-motif mutagenesis, nuclear localization imaging\",\n      \"pmids\": [\"15121840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CK1 isoform specificity not fully resolved\", \"Mechanism of signal-induced complex dissociation upon activation not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected CK1\\u03b1 to mitotic regulation and to negative control of canonical Wnt output by phosphorylating FADD (spindle-pole localized) and LEF-1 to disrupt the LEF-1/\\u03b2-catenin complex.\",\n      \"evidence\": \"In vitro kinase assays, co-IP, immunofluorescence, EMSA, luciferase reporter, splenocyte proliferation\",\n      \"pmids\": [\"16061179\", \"15747065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CK1\\u03b1 is recruited to spindle poles not yet defined\", \"Physiological trigger of LEF-1 phosphorylation in vivo unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the docking determinants for substrate recognition on \\u03b2-catenin, showing the first armadillo repeat and \\u03b1-catenin binding govern CK1 access to Ser45.\",\n      \"evidence\": \"In vitro kinase assay with deletion mutants, Km determination, competition assay\",\n      \"pmids\": [\"17172446\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconstituted in vitro; in-complex regulation by axin/APC not addressed here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended CK1\\u03b1 substrate scope to RNA-binding proteins and small GTPases, phosphorylating hnRNP-C, Star-PAP, and RhoB to modulate RNA binding, mRNA expression, and cytoskeletal dynamics.\",\n      \"evidence\": \"MS kinase identification, in vitro kinase assays, co-IP, RNA-binding and immunofluorescence functional readouts\",\n      \"pmids\": [\"15687492\", \"18305108\", \"18590726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular contexts for each substrate not fully linked\", \"PI-4,5-P2 sensitivity of CK1\\u03b1 within Star-PAP complex not structurally explained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed both an autoregulatory brake (C-terminal autophosphorylation inhibits activity) and a p53-suppressive function via a stable MDM2\\u2013CK1\\u03b1 complex with defined S20 docking on full-length p53.\",\n      \"evidence\": \"MS autophosphorylation site mapping, phosphatase activation cycle, mutagenesis, reciprocal endogenous co-IP, RNAi, chemical inhibition\",\n      \"pmids\": [\"19115251\", \"19759023\", \"20041275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the MDM2\\u2013CK1\\u03b1 interface not resolved\", \"How autophosphorylation status integrates with substrate selection in vivo unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed CK1 in the Hippo and circadian pathways by phosphorylating YAP Ser381 to create a \\u03b2-TRCP phosphodegron and PER1 to drive its degradation, generalizing the phosphodegron mechanism.\",\n      \"evidence\": \"In vitro kinase cascade reconstitution, phospho-antibodies, ubiquitination assay; affinity-MS, siRNA, circadian reporter assays\",\n      \"pmids\": [\"20048001\", \"21179498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions of CK1\\u03b1 vs CK1\\u03b4/\\u03b5 to YAP turnover not isolated\", \"Clock kinase network redundancy complicates CK1\\u03b1-specific assignment\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated in vivo that CK1\\u03b1 is a destruction-complex component and tumour suppressor whose ablation co-activates Wnt and p53, and detailed its dual roles in Hedgehog (Smoothened activation) and Wnt receptor signalling.\",\n      \"evidence\": \"Conditional knockout mouse epistasis; in vitro kinase, mutagenesis, immunofluorescence, Hh/Wnt reporter and co-IP epistasis\",\n      \"pmids\": [\"21331045\", \"21695114\", \"21606194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context that switches CK1\\u03b1 between Smoothened activation and \\u03b2-catenin destruction not defined\", \"Mechanism coupling CK1\\u03b1 loss to p53 activation in gut left open\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Positioned CK1\\u03b1 upstream of p53 in leukemia survival and refined Hedgehog control, showing CK1\\u03b1 knockdown induces p53-dependent myeloid differentiation and CK1 sustains Ci/Gli activator isoforms.\",\n      \"evidence\": \"In vivo pooled shRNA screen, p53-null rescue epistasis, expression profiling; in vitro kinase, mutagenesis, Drosophila and mammalian Hh assays\",\n      \"pmids\": [\"24616378\", \"25512501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CK1\\u03b1 substrate linking it to Rps6/p53 axis in AML not identified\", \"Switch between Ci/Gli degradation and stabilization not mechanistically reconciled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the therapeutically pivotal IMiD mechanism: lenalidomide converts CK1\\u03b1 into a CRL4(CRBN) neosubstrate, and del(5q) CK1\\u03b1 haploinsufficiency underlies the MDS therapeutic window; also linked CK1\\u03b1\\u2013FADD to oncogenic KRAS-driven mitosis.\",\n      \"evidence\": \"Ubiquitination assays, IP, mouse-human CRBN swap rescue, MS; conditional KO mouse, MS, in vivo imaging\",\n      \"pmids\": [\"26131937\", \"25628462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why CK1\\u03b1 dosage sensitivity is unique to del(5q) not fully explained at the time\", \"Endogenous (IMiD-independent) regulators of CK1\\u03b1 turnover unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided the structural basis of IMiD-dependent neosubstrate recognition, showing CRBN and lenalidomide jointly form the binding surface for a CK1\\u03b1 N-lobe \\u03b2-hairpin loop.\",\n      \"evidence\": \"2.45 \\u00c5 X-ray crystallography of DDB1-CRBN\\u2013lenalidomide\\u2013CK1\\u03b1, binding assays, mutagenesis\",\n      \"pmids\": [\"26909574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address selectivity among CK1 isoforms for degradation\", \"Native CK1\\u03b1 regulation independent of CRBN not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Expanded CK1\\u03b1 into epithelial/progenitor biology and oncogenic RAS signalling: it phosphorylates PRMT1 to maintain epidermal progenitors, FOXO4 to drive its degradation, and its loss stabilizes both \\u03b2-catenin and p53 to drive p53/KitL-dependent pigmentation.\",\n      \"evidence\": \"MS interactomes, co-IP, in vitro kinase, conditional/human mosaic knockouts; double KO mice with pharmacological rescue; CK1\\u03b1 activator xenografts\",\n      \"pmids\": [\"28943242\", \"28945225\", \"28878021\", \"28655862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific determinants of CK1\\u03b1 substrate choice not unified\", \"Whether CK1\\u03b1 activators are broadly tractable therapeutically remains untested beyond CRC models\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified CK1\\u03b1 as an executioner kinase for cell-fate decisions, activating p63 in oocyte DNA-damage QC, stabilizing PTEN to promote autophagy/tumour suppression, and cooperating with DBT in clock PER localization.\",\n      \"evidence\": \"Biochemical/structural p63 assays with in vivo rescue; co-IP, ubiquitination, xenografts; Drosophila genetics and fractionation\",\n      \"pmids\": [\"29483652\", \"29593330\", \"30373768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CK1\\u03b1 is activated specifically upon DNA damage in oocytes unclear\", \"CK1\\u03b1\\u2013PTEN versus CK1\\u03b1\\u2013p53 tumour-suppressive arms not integrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established scaffold-directed spatial control of CK1\\u03b1 by FAM83D, which recruits the kinase to the mitotic spindle to ensure correct spindle positioning and mitotic timing.\",\n      \"evidence\": \"CRISPR knockin of CK1\\u03b1-binding-deficient FAM83D, live-cell imaging, knockout, artificial re-delivery rescue\",\n      \"pmids\": [\"31338967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spindle-localized CK1\\u03b1 substrates not enumerated\", \"Relationship to FADD-spindle phosphorylation not connected\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined CK1\\u03b1 as a necrosome component phosphorylating RIPK3 Ser227 to license necroptosis, and identified additional substrate (CBX4) and localization controls (FAM83F farnesylation; RNF43-mediated membrane trapping in cancer).\",\n      \"evidence\": \"Tandem IP, in vitro kinase, RIPK3 recognition-motif rescue, necroptosis assays; CBX4 phospho/ubiquitination assays; CRISPR knockin and PLA\",\n      \"pmids\": [\"31932442\", \"32111827\", \"33361109\", \"32965059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform redundancy (\\u03b1/\\u03b4/\\u03b5) in necrosome not dissected\", \"How membrane-trapped CK1\\u03b1 alters its destruction-complex function quantitatively unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a second, conformational layer of autoregulation\\u2014\\u03b1G-helix threonine autophosphorylation remodels the substrate cleft to rewire substrate selectivity\\u2014and showed PER itself scaffolds CK1 to control clock phosphorylation in vivo.\",\n      \"evidence\": \"Crystal structure, MD simulations, kinase assays, phosphoproteomics; CRISPR knock-in mice with locomotor and biochemical readouts\",\n      \"pmids\": [\"35353987\", \"35810166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signals controlling \\u03b1G autophosphorylation in mammalian cells unknown\", \"How conformational rewiring intersects with scaffold-based targeting not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided structural mechanism for substrate-driven product inhibition of CK1, with the phosphorylated PER2 FASP region docking near the active site to inhibit the kinase and tune circadian period.\",\n      \"evidence\": \"Co-crystal structure of pFASP\\u2013CK1\\u03b4, MD simulations, mutagenesis, circadian period assays in human cells\",\n      \"pmids\": [\"37207626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Studied with CK1\\u03b4; generality to CK1\\u03b1 not directly shown\", \"Whether other substrates exert analogous product inhibition unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Advanced CK1\\u03b1 as a tractable degradation target with a selective CRBN-based degrader (SJ3149) whose antiproliferative activity tracks with p53 (Nutlin-3a) sensitivity, reinforcing the CK1\\u03b1\\u2013p53 therapeutic axis.\",\n      \"evidence\": \"Structure-guided medicinal chemistry, co-crystal with CK1\\u03b1+CRBN+DDB1, proteomics, PRISM screen, viability panel\",\n      \"pmids\": [\"38228616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"p53 link inferred from correlation rather than direct mechanism\", \"On-target versus off-target degradation contributions to phenotype not fully separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CK1\\u03b1's constitutive activity is selectively channeled to opposing outcomes (e.g., \\u03b2-catenin destruction vs Smoothened activation; p53 suppression vs activation) through the combined logic of scaffold-based localization, docking-site recognition, and autophosphorylation-driven conformational rewiring remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating scaffold targeting, substrate docking, and \\u03b1G/C-terminal autophosphorylation states\", \"Endogenous signals controlling CK1\\u03b1 abundance and activity in each pathway incompletely defined\", \"Isoform-specific (\\u03b1 vs \\u03b4/\\u03b5) contributions to many substrates unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 5, 6, 16, 17, 22, 24, 25]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [3, 24, 30, 38]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [37]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13, 14, 37]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [6, 28, 39]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [21, 29, 33]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 5, 21, 22, 24]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [6, 28, 39]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15, 16]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [4, 40, 41, 42]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 9, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [\n      \"\\u03b2-catenin destruction complex\",\n      \"necrosome\",\n      \"MDM2-CK1\\u03b1 complex\",\n      \"Star-PAP complex\"\n    ],\n    \"partners\": [\n      \"MDM2\",\n      \"AXIN1\",\n      \"FAM83D\",\n      \"FAM83F\",\n      \"PER2\",\n      \"CRBN\",\n      \"RIPK3\",\n      \"PTEN\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}